Personalised medicine is a term that has been bandied about for years, but the concept is now becoming a reality with the advent of gene sequencing
After reading this feature you will be able to:
- Explain the concept of personalised medicine
- Discuss the role of genome and RNA sequencing
- Describe some examples of personalised medicine in practice.
- Genome sequencing can reveal mutations in DNA that influence diseases
- Personalised medicine can be used to predict a person's risk for a particular disease
- Researchers are experimenting with nanocarriers that can precisely target a specific disease site.
It was back in 2015 when Sir Bruce Keogh, then NHS England’s national medical director, outlined an emerging strategy for personalised medicine in the NHS.
This would entail a move away from a ‘one size fits all’ approach to the treatment and care of patients with a particular condition, to one using diagnostics, genomics, data analytics and other emerging technologies to identify the underlying causes of disease.
At that time the main focus of the NHS in this area was its ‘100,000 Genomes’ project, which sought to embed genomic technologies into clinical care pathways. This has led the NHS to become one of the most advanced healthcare systems in the world in the use of genomic medicine – but there was more ambition to the strategy than that. It anticipated:
- Improved prevention based on identifying an underlying predisposition for a condition
- Earlier diagnosis of disease as a result of identifying abnormality earlier
- More precise diagnosis based on cause
- Targeted interventions through the use of companion diagnostics to identify and stratify effective treatments.
Three years later, towards the end of 2018, the NHS announced that the first children to receive a "game-changing personalised therapy for cancer" were starting treatment at Great Ormond Street Hospital in London.
The children were given CAR-T therapy to treat B-cell acute lymphoblastic leukaemia. CAR-T is a complex type of immunotherapy that involves collecting and using the patients’ own immune cells to target their cancer in a process which is completed over a number of weeks.
Of course, the concept of personalised medicine – or precision medicine – is not new. Clinicians have been working to tailor treatment to people’s individual health needs throughout history. The difference now is that it is increasingly possible to predict how each individual will respond to specific interventions, or to identify who is at risk of developing an illness. This is largely down to the ability to genotype a patient’s DNA.
A sign of the times
A sure sign that personalised medicine is coming into the mainstream is when the regulators get involved.
In August the MHRA launched a consultation on a new regulatory framework to ensure the safety and efficacy of products where they fall into the point-of-care (PoC) category.
The MHRA says that technology is enabling the creation of new types of medicinal products. They have features such as a very short shelf life and may be highly personalised, requiring them to be manufactured and supplied at the point of care.
This is very different from traditional pharmaceuticals that typically have a shelf life measured in years and are manufactured at large scale in a relatively small number of factory-based sites. Medicines regulation is geared to and supports this kind of medicines manufacture. However, PoC products – where manufacture is in the hospital and supply to the patient is immediate – do not fit this ‘standard model’ of regulation.
The MHRA says it has seen PoC products that span much of the pharmaceutical spectrum. They include some types of advanced therapy medicinal products (ATMPs include cell therapy, gene therapy and tissue engineered products), 3D printed products, blood products and medical gases.
Genome and RNA sequencing
Genome sequencing can reveal mutations in DNA that influence diseases ranging from cystic fibrosis to cancer. Another method, called RNA-seq, can show which RNA molecules are involved with specific diseases. Unlike DNA, levels of RNA can change in response to the environment, so sequencing RNA can provide a broader understanding of a person’s state of health.
To understand if a mutation is connected to a certain disease, researchers often carry out a genome-wide association study (GWAS) for a specific condition, sequencing the genome of many patients to look for shared mutations in the genome. Mutations found to be related to a disease can then be used to diagnose it in future patients.
Personalised medicine can also be used to predict a person’s risk for a particular disease, based on one or even several genes. This approach uses the same sequencing technology to focus on the evaluation of disease risk, allowing preventive treatment to be started before the disease presents itself in the patient.
A new word in the lexicon is pharmaco- genomics, which uses an individual’s genome to provide a more informed and tailored approach to medication. Genetic information from the individual can help prevent adverse events, allow for appropriate dosages and create maximum efficacy (see panel for examples).
There are several genes known to be largely responsible for variances in drug metabolism and response. They include the cytochrome P450 family of enzymes, which account for the metabolism of 70-90 per cent of drugs.
Understanding a patient’s genotype can indicate how fast a drug might be metabolised. For example, codeine is a prodrug that requires metabolism to morphine, which provides the therapeutic effect of pain relief.
Compare someone with the CYP2D6 gene who has an extensive metaboliser phenotype to someone who is an intermediate metaboliser. Although both individuals might be taking the same dose of codeine, one could potentially lack the therapeutic benefits of codeine due to the decreased conversion rate of codeine to its active metabolite morphine.
Many of the headline stories about personalised medicines involve cancer treatments. Pharmaco-genomics tests can be used to identify which patients are most likely to respond to certain cancer drugs:
- Herceptin (trastuzumab) used in breast cancer is directed to the 30 per cent of breast cancers with an over-expression of HER-2 protein, which respond to the drug
- Vemurafenib is used to treat melanoma, where the late-stage prognosis has been dismal – but 60 per cent of patients have a defect in their BRAF gene, and this drug benefits those with this defect
- Most people with chronic myeloid leukaemia have an abnormal BCR-ABL1 gene (the Philadelphia chromosome). Those who test positive may be treated with imatinib or dasatinib
- Tamoxifen used to be a drug commonly prescribed to women with ER+ breast cancer, but 65 per cent of women initially taking it developed resistance. Research discovered that women with certain mutations in their CYP2D6 gene were not able to efficiently break down tamoxifen, making it an ineffective treatment for their cancer. Women are now genotyped for those specific mutations, so that they can have the most effective therapy.
Genome sequencing is no longer just the preserve of the NHS. Although a fledgling sector in the UK, companies such as AffinityDNA, 23andMe and tellmeGen offer direct-to-consumer genome sequencing. As well as paternity tests, genetic health DNA tests are on offer to help guide diet and nutrition, fitness, intolerances,gut microbiome, lifestyle and skincare.
As a footnote, it is not only genome sequencing that makes personalised medicine possible: data and informatics, and wearable technology all play their part. Databases play an integral role, and it is important to know which population gene samples are taken from to prevent bias.
So where does personalised medicine go next?
Some examples of personalised medicine
- Familial hypercholesterolaemia causes raised cholesterol and is a significant risk for heart attack and other cardiac events in the under-50s. It affects one in 250 people, but only one in six of these are diagnosed. By using both genetic and biochemical testing, familial hypercholesterolaemia can be identified and affected people can receive inexpensive medicines to protect them from future problems.
- Warfarin is an effective treatment to prevent blood clots, but patients show a 40-fold difference in the dose needed. The ‘trial and error’ approach to adjust dosage for an individual means some have significant problems as their treatment is worked out. The discovery of variants in the two genes that encode an individual’s anticoagulant response means that their gene profile can be used to determine optimum doses of warfarin. Appropriate testing can be used to arrive at the right dose sooner, cutting side-effects and improving outcomes.
- Abacavir is a first-line antiretroviral treatment for HIV. However, about one in 17 people have a bad reaction to the drug – which, at worst, can be fatal – due to a variation in their immune system. All patients now have a specific genomic test before they start taking abacavir, which identifies those who would have an allergic reaction.
- Diabetes: the standard approach to newly-diagnosed type 1 diabetes is regular insulin injections. However, other forms of diabetes can appear clinically similar to type 1, but have different underlying causes. A simple genetic test can identify patients who can be better treated using oral medication or managed by no treatment at all.
New ways for delivering personalised drugs to disease sites in the body are being looked at. Researchers are experimenting with nanocarriers that can precisely target the specific disease site by using real-time imaging and an understanding of the pharmacodynamics of drug delivery.
Several candidate nanocarriers are being investigated, including iron oxide and gold nanoparticles, and carbon nanotubes. Altering the surface chemistry allows the nanoparticles to be loaded with drugs, avoiding the body’s immune response, making nanoparticle-based drug delivery possible.
Nanocarriers’ targeting strategies vary according to the disease. For example, if the disease is cancer, a common approach is to identify the biomarker expressed on the surface of cancer cells and to load its associated targeting vector onto the nanocarrier to achieve recognition and binding. Personalised medicine could get a lot more personal yet!